title: Clinicopathological features including hormonal receptor expression and survival in young endometrial cancer patients: a case control study.
abstract: OBJECTIVE
  To compare clinicopathological features, including hormonal receptor expression and survival, in young Thai endometrial carcinoma (EMC) patients with older patients.
  
  
  METHODS
  Young EMC patients aged ≤45 years, treated in the institution from 1992 to 2008, were identified as cases. Controls included EMC patients aged >45 years who had an operation on the nearest dates to the cases. Clinicopathological data and survival of the cases and controls were compared.
  
  
  RESULTS
  Mean ages of 41 cases and 123 controls were 40.4 ± 3.7 years and 58.4 ± 8.3 years, respectively. Cases were significantly different from controls in terms of having more nulliparity (58% vs 25%), less medical illness (57% vs 79%), more low-grade tumors (49% vs 14%), more positive estrogen (78% vs 56%) and progesterone (97% vs 61%) receptors expression, and fewer nodal metastases (3% vs 21%). Adjuvant therapy was administered in 29% of the cases and 46% of the controls. From a median follow up of 51 months, cases had significantly fewer progression events and recurrence (5% vs 19%), cancer-related deaths (2% vs 16%), and all deaths (5% vs 23%), with significantly longer 5-year disease-free (97.2% vs 79.6%, p=0.023), cancer-specific (97.1% vs 83.2%, p=0.020), and overall survival (93.1% vs 78.8% p=0.005) than controls as determined by univariate analysis. Survival of cases and controls were not significantly different after adjusting for other prognostic factors.
  
  
  CONCLUSIONS
  Young Thai EMC patients had more favorable clinicopathological features with significantly longer survival than older patients as determined by univariate analysis.
authors.affiliation: Department of Obstetrics and Gynecology, Bangkok Metropolitan Administration Medical College and Vajira Hospital, Bangkok, Thailand. siriwanonco@yahoo.com
authors.forename: Siriwan
authors.initials: S
authors.lastname: Tangjitgamol
authors.forename: Sumonmal
authors.initials: S
authors.lastname: Manusirivithaya
authors.forename: Sunamchok
authors.initials: S
authors.lastname: Srijaipracharoen
authors.forename: Sujitra
authors.initials: S
authors.lastname: Tanvanich
authors.forename: Jakkapan
authors.initials: J
authors.lastname: Khunnarong
authors.forename: Thaovalai
authors.initials: T
authors.lastname: Thavaramara
authors.forename: Kamol
authors.initials: K
authors.lastname: Pataradool
authors.forename: Surawute
authors.initials: S
authors.lastname: Leelahakorn
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D004717:Endometrium / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D015996:Survival Rate
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone